Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
复制标题
DOI：
10.3389/fmed.2019.00086
复制
发表时间：
2019-04-26
影响因子：
3.9
通讯作者：
Aiba, Setsuya
中科院分区：
文献类型：
--
作者：
Fujimura, Taku;Sato, Yota;Aiba, Setsuya
抗程序性细胞死亡蛋白1（PD1）抗体广泛用于治疗各种癌症。基于PD1抗体的免疫疗法，即nivolumab和ipilimumab的联合给药，是最佳的免疫疗法之一，特别是在具有高肿瘤突变负荷的晚期黑色素瘤中。由于这种联合治疗导致晚期黑色素瘤患者发生严重免疫相关不良事件（irAE）的频率很高，因此需要生物标志物来评估nivolumab的疗效，以避免ipilimumab引起的严重irAE。本研究分析了46例接受纳武利尤单抗治疗的晚期皮肤黑色素瘤患者的CXCL5、CXCL10和CCL22的基线血清水平。应答者的基线血清CXCL5水平显著高于无应答者。相比之下，应答者和非应答者之间的基线血清CXCL10和CCL22水平没有显著差异。这些结果表明，基线血清水平的CXCL5可能是有用的生物标志物，用于识别晚期皮肤黑色素瘤患者最有可能受益于抗黑色素瘤免疫治疗。
Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly higher in responders than in non-responders. In contrast, there were no significant differences in baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.